Advanced search
Publication Cover
Journal of Chemotherapy Volume 30, 2018 - Issue 6-8
Submit an article Journal homepage
265
Views
5
CrossRef citations to date
0
Altmetric
Case Report

Acute kidney injury: an unusual complication of posaconazole use

Akaninyene OtuUniversity of Calabar, Calabar, Cross River State, Nigeria, ;The National Aspergillosis Centre, 2nd Floor Education and Research Centre, Manchester University NHS Foundation Trust, Manchester, UK, Correspondence[email protected]
View further author information
,
Felix BongominThe National Aspergillosis Centre, 2nd Floor Education and Research Centre, Manchester University NHS Foundation Trust, Manchester, UK, ;Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, View further author information
,
Chris KosmidisThe National Aspergillosis Centre, 2nd Floor Education and Research Centre, Manchester University NHS Foundation Trust, Manchester, UK, ;Manchester Academic Health Science Centre, 2nd Floor Education and Research Centre, Manchester University NHS Foundation Trust, Manchester, UKView further author information
&
David W. DenningThe National Aspergillosis Centre, 2nd Floor Education and Research Centre, Manchester University NHS Foundation Trust, Manchester, UK, ;Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, ;Manchester Academic Health Science Centre, 2nd Floor Education and Research Centre, Manchester University NHS Foundation Trust, Manchester, UKView further author information
Pages 380-383 | Received 13 Mar 2018, Accepted 05 Sep 2018, Published online: 19 Jan 2019

References

  • Redahan L, Murray P. Biomarkers of drug-induced kidney injury. Curr Opin Crit Care. 2017;23(6):463–9
  • Khajavi Rad A, Mohebbati R, Hosseinian S. Drug-induced nephrotoxicity and medicinal plants. Iran J Kidney Dis. 2017;11(3):169–79.
  • Singh M, Karakala N, Shah S V. Long-term adverse events associated with acute kidney injury. J Ren Nutr. 2017;27(6):462–4.
  • Jacinto PL, Chandrasekar P. Safety of posaconazole. Expert Opin Drug Saf. 2013;12(2):265–74.
  • Merck Sharp & Dohme Limited. 2017. Noxafil (r) [package insert]. Available online at: https://www.medicines.org.uk/emc/medicine/28880 [Accessed 24 December 2017].
  • Felton TW, Baxter C, Moore CB. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis. 2010;51(12):1383–91.
  • Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47:45–68
  • Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726–34.
  • Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9.
  • Keirns J, Desai A, Kowalski D, Lademacher C, Mujais S, Parker B. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther. 2017;101(6):782–90.
  • Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5(12):775–85.
  • Boglione-Kerrien C, Picard S, Tron C, Nimubona S, Gangneux JP, Lalannae S. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies. J Cancer Res Clin Oncol. 2017;144(1):127–34.
  • Ashbee HR, Barnes RA, Johnson EM Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the british society for medical mycology. J Antimicrob Chemother. 2014;69(5):1162–76.
  • Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24(2):64–71.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.